logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yukinori Ozaki

breast oncology center
H指数:16
被引数:832

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer

早期三阴性及雌激素受体低表达、HER2阴性乳腺癌患者接受新辅助 pembrolizumab 联合化疗及辅助 pembrolizumab 治疗的真实世界无事件生存情况

BMC Cancer
IF3.4
2026-10-060
OAAI
Yosuke Aoyama; Yukinori Ozaki; Masahiro Kuno; Jun Masuda; Meiko Nishimura; Mami Kurata; Lina Inagaki; Mari Hosonaga; Ippei Fukada; Emi Taniguchi; Yuri Kimura; Tetsuyo Maeda; Kazuyo Yoshida; Nami Yamashita; Takayuki Kobayashi; Toshimi Takano; Takayuki Ueno
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer

曲拉妥单抗德鲁克替康后，在激素受体阳性、HER2阴性转移性乳腺癌中的真实世界结局

Breast Cancer
IF2.9
2026-09-020
OAAI
Yosuke Aoyama; Yukinori Ozaki; Masahiro Kuno; Rika Kizawa; Jun Masuda; Meiko Nishimura; Mami Kurata; Lina Inagaki; Mari Hosonaga; Ippei Fukada; Tetsuyo Maeda; Kazuyo Yoshida; Nami Yamashita; Takayuki Kobayashi; Toshimi Takano; Takayuki Ueno
Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE

转移性三阴性乳腺癌患者中阿替利珠单抗联合白蛋白结合型紫杉醇的队列观察性研究：JBCRG-C08/ATTRIBUTE

npj Breast Cancer
IF7.6
2026-06-260
OA
Tatsunori Shimoi; Nobuhiro Shibata; Masahiro Kitada; Michiko Tsuneizumi; Mitsugu Yamamoto; Yukinori Ozaki; Yumi Fujimoto; Sayuri Akiyoshi; Naoki Hashimoto; Miki Yamaguchi; Yutaka Yamamoto; Norikazu Masuda; Hiroshi Tada; Takashi Yamanaka; Yuichiro Kikawa; Tetsuhiko Taira; Shizuka Nakagawa; Taizo Takahashi; Mari S. Oba; Naoki Niikura
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)

随机化、多中心II期研究：贝伐珠单抗和紫杉醇诱导后使用阿替利珠单抗和nab-紫杉醇治疗PD-L1阳性转移性三阴性乳腺癌患者的方案（INDUCE试验[JBCRG-M10]）

BMJ Open
IF2.3
2026-05-130
PRE
Ozaki, Yukinori; Koyama, Shohei; Morita, Satoshi; Miyashita, Minoru; Tokuda, Emi; Shimoi, Tatsunori; Fukuoka, Megumi; Masuda, Hiroko; Takano, Yuko; Shibata, Nobuhiro; Yoshinami, Tetsuhiro; Murakami, Akari; Tamaki, Kentaro; Ishiguro, Hiroshi; Saji, Shigehira; Miwa, Asako; Matsunaga, Junko; Zheng, Yue; Nishikawa, Hiroyoshi; Masuda, Norikazu
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial

原发肿瘤切除可降低新诊断IV期乳腺癌的主要局部并发症风险：来自JCOG1017随机对照试验的二次数据分析

bjs
IF0
2026-05-010
PRE
Makoto Ishitobi; Kiyo Tanaka; Akihiko Shimomura; Takashi Yamanaka; Takahiro Tsukioki; Hiroji Iwata; Fumikata Hara; Tomomi Fujisawa; Keita Sasaki; Riku Kajikawa; Takehiko Sakai; Yasuaki Sagara; Hideo Shigematsu; Yukinori Ozaki; Kazuki Nozawa; Kazuki Sudo; Yoichi Naito; Kaori Terata; Toshiyuki Ishiba; Haruhiko Fukuda; Tadahiko Shien
Characterizing heterogeneous cis-regulatory elements in gene regulatory programs associated with breast cancer

表征与乳腺癌相关的基因调控程序中的异质性顺式调控元件

Genome Medicine
IF11.2
2025-11-270
OAAI
Chisa Hori; Kohei Kumegawa; Sumito Saeki; Yoko Takahashi; Liying Yang; Tomoyoshi Nakadai; Kazutaka Otsuji; Chikako Takahata; Yukinori Ozaki; Natsue Uehiro; Yurie Haruyama; Tomo Osako; Toshimi Takano; Seiichi Mori; Tetsuo Noda; Satoshi Fujii; Shinji Ohno; Takayuki Ueno; Reo Maruyama
Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study

激素受体阳性HER2阴性乳腺癌局部区域复发切除术后辅助化疗与预后的关系：一项多中心回顾性研究

ESMO Open
IF8.3
2025-11-070
OAAI
Y. Ozaki; E. Tokuda; Y. Sagara; F. Hara; S. Sasada; M. Sawaki; C. Kanbayashi; T. Yamanaka; T. Onishi; Y. Fujiki; A. Suto; Y. Takahashi; E. Tokunaga; T. Aruga; R. Nakamura; T. Fujisawa; S. Saji; H. Iwata; T. Shien
Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study

奥氮平用于接受曲妥珠单抗德鲁克替康治疗的乳腺癌患者的恶心和呕吐：ERICA研究的简明语言摘要

Future Oncology
IF2.6
2025-10-240
OAAI
Hitomi Sakai; Junji Tsurutani; Yukinori Ozaki; Hiroshi Ishiguro; Kazuki Nozawa; Takashi Yamanaka; Kenjiro Aogi; Koji Matsumoto; Tsutomu Iwasa; Mariko Tokiwa; Michiko Tsuneizumi; Yasuo Miyoshi; Chiyoe Kitagawa; Mitsugu Yamamoto; Yuko Takano; Chiyo K. Imamura; Yasutaka Chiba; Daisuke Takiguchi; Takayuki Ezumi; Toshimi Takano
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer

更正：来自日本的真实世界证据显示，在接受CDK4/6抑制剂联合内分泌疗法作为一线或二线治疗激素受体阳性、HER2阴性晚期或转移性乳腺癌患者的生存结局及治疗顺序方面的数据。

Breast Cancer
IF2.9
2025-06-230
OAAI
Tetsuhiro Yoshinami; Yuko Takano; Yukinori Ozaki; Yukiko Kajiwara; Mitsugu Yamamoto; Ken-ichi Watanabe; Masami Tsukabe; Fumie Fujisawa; Shigenori E. Nagai; Nobuhiro Shibata; Chiya Oshiro; Hiroko Bando; Nobuyuki Tsunoda; Kazuhiko Yamagami; Kei Koizumi; Masahiro Takada; Naoko Toriguchi; Nobuyuki Sekine; Tsutomu Kawaguchi; Shigehira Saji; Yasuaki Sagara; Satoshi Morita; Norikazu Masuda
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

来自日本的真实世界证据，关于接受CDK4/6抑制剂联合内分泌治疗作为激素受体阳性、HER2阴性晚期或转移性乳腺癌的一线或二线治疗患者的生存结局及治疗顺序。

BREAST CANCER
IF2.9
2025-05-200
OA
Yoshinami, Tetsuhiro; Takano, Yuko; Ozaki, Yukinori; Kajiwara, Yukiko; Yamamoto, Mitsugu; Watanabe, Ken-ichi; Tsukabe, Masami; Fujisawa, Fumie; Nagai, Shigenori E.; Shibata, Nobuhiro; Oshiro, Chiya; Bando, Hiroko; Tsunoda, Nobuyuki; Yamagami, Kazuhiko; Koizumi, Kei; Takada, Masahiro; Toriguchi, Naoko; Sekine, Nobuyuki; Kawaguchi, Tsutomu; Saji, Shigehira; Sagara, Yasuaki; Morita, Satoshi; Masuda, Norikazu
Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B)

激素受体阳性，HER2-negative乳腺癌患者早期复发的危险因素: 日本的一项回顾性队列研究 (WJOG15721B)

BREAST CANCER
IF2.9
2025-04-010
OAAI
Watanuki, Rurina; Sakai, Hitomi; Takehara, Yuri; Yoshida, Atsushi; Hayashi, Naoki; Ozaki, Yukinori; Kataoka, Akemi; Uehiro, Natsue; Kamio, Hidenori; Onishi, Mai; Fushimi, Atsushi; Ikeno, Takashi; Wakabayashi, Masashi; Iida, Mayumi; Kawaguchi, Tsutomu; Takano, Toshimi
Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022

剂量密集化疗在预防性使用培非格司亭的情况下对早期乳腺癌的疗效与安全性：一项基于《2022年G-CSF使用临床实践指南》的系统评价与荟萃分析

international journal of oncology
IF2.8
2025-02-120
PRE
Yokoe, Takamichi; Yoshinami, Tetsuhiro; Nozawa, Kazuki; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Ichihara, Eiki; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study

新辅助帕博利珠单抗联合化疗治疗早期三阴性和雌激素受体低下的HER2-negative乳腺癌的疗效和可行性: 一项日本单机构真实世界研究

BREAST CANCER
IF2.9
2024-12-070
PRE
Aoyama, Yosuke; Ozaki, Yukinori; Kizawa, Rika; Masuda, Jun; Kawai, Saori; Kurata, Mami; Maeda, Tetsuyo; Yoshida, Kazuyo; Yamashita, Nami; Nishimura, Meiko; Hosonaga, Mari; Fukada, Ippei; Hara, Fumikata; Kobayashi, Takayuki; Takano, Toshimi; Ueno, Takayuki
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)

一项多中心、随机、双盲、安慰剂对照的研究，评估以olanzapine为基础的三联抗恶心疗法对trastuzumab deruxtecan在转移性乳腺癌患者中诱导的延迟性和持续性恶心呕吐的预防作用：ERICA研究（WJOG14320B）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Sakai, H.; Tsurutani, J.; Ozaki, Y.; Ishiguro, H.; Nozawa, K.; Yamanaka, T.; Kameoka, H.; Matsumoto, K.; Iwasa, T.; Tokiwa, M.; Tsuneizumi, M.; Miyoshi, Y.; Kitagawa, C.; Yamamoto, M.; Takano, Y.; Imamura, C. K.; Chiba, Y.; Takiguchi, D.; Ezumi, T.; Takano, T.
A Randomized Controlled Trial of Metastasisdirected Therapy for Oligometastases in Breast Cancer (OLIGAMI trial; JCOG2110)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Ishiba, Toshiyuki; Nishibuchi, Ikuno; Hara, Fumitaka; Sasaki, Keita; Sadate, Ryo; Sekino, Yuta; Machida, Ryunosuke; Fukuda, Haruhiko; Kogawa, Takahiro; Fujisawa, Tomomi; Sagara, Yasuaki; Naito, Yoichi; Terata, Kaori; Ozaki, Yukinori; Shimomura, Akihiko; Sakai, Takehiko; Kanbayashi, Chizuko; Iwatani, Tsuguo; Shigematsu, Hideo; Tamura, Kenji; Mizowaki, Takashi; Yoshimura, Michio; Shikama, Naoto; Shien, Tadahiko; Iwata, Hiroji
The Prognostic Impact of Adjuvant Endocrine Therapy by Age for Patients with Small Estrogen Receptor-Positive (ER plus ), Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Takahashi, Yuko; Sasada, Shinsuke; Kondo, Naoto; Hashimoto, Hiroya; Terata, Kaori; Kida, Kumiko; Sagara, Yasuaki; Naito, Yoichi; Anan, Keisei; Ueno, Takayuki; Suto, Akihiko; Kanbayashi, Chizuko; Takahashi, Mina; Nakamura, Rikiya; Ishiba, Toshiyuki; Tsuneizumi, Michiko; Nishimura, Seiichiro; Ozaki, Yukinori; Shimomura, Akihiko; Sakai, Takehiko; Iwatani, Tsuguo; Shigematsu, Hideo

研究方向

暂未获取到该数据
T
Toshimi Takano
H 指数:36论文数:394被引数:8,038
T
Takayuki Ueno
H 指数:42论文数:395被引数:7,250
T
Takayuki Kobayashi
H 指数:19论文数:133被引数:1,099
F
Fumikata Hara
H 指数:20论文数:171被引数:1,392
Y
Yuko Tanabe
H 指数:30论文数:225被引数:2,759
S
Shinji Ohno
H 指数:62论文数:565被引数:2.3万
J
Junji Tsurutani
H 指数:53论文数:366被引数:1.8万
H
Hidetaka Kawabata
H 指数:17论文数:125被引数:1,355
M
Meiko Nishimura
H 指数:9论文数:60被引数:243
I
Ippei Fukada
H 指数:11论文数:90被引数:498